Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1859)
All Articles published online
|
Feb 14, 2006 (publication date) through Jul 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Li Y, Wo JM, Ray MB, Jones W, Su RR, Ellis S, Martin RCG. Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett’s esophagus to adenocarcinoma. World J Gastroenterol 2006; 12(6): 928-934 [PMID: 16521222 DOI: 10.3748/wjg.v12.i6.928] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i6/928.htm |
| Number | Citing Articles |
| 1 |
Patrick Yachimski, Mari Mino-Kenudson, Margaret E. Sherwood, William P. Puricelli, Norman S. Nishioka, Gregory Y. Lauwers. Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett’s esophagus with high-grade dysplasia or intramucosal carcinoma. Virchows Archiv 2011; 459(6): 581 doi: 10.1007/s00428-011-1167-x
|
| 2 |
Gen Kusaka, Kaname Uno, Katsunori Iijima, Hiroyuki Endo, Naoki Asano, Tomoyuki Koike, Akira Imatani, Tooru Shimosegawa. The role of nitric oxide in the induction of caudal-type homeobox 2 through epidermal growth factor receptor in the development of Barrett's esophagus. Scandinavian Journal of Gastroenterology 2012; 47(10): 1148 doi: 10.3109/00365521.2012.703232
|
| 3 |
S. MEHTA, A. BODDY, I. T. JOHNSON, M. RHODES. Systematic review: cyclo‐oxygenase‐2 in human oesophageal adenocarcinogenesis. Alimentary Pharmacology & Therapeutics 2006; 24(9): 1321 doi: 10.1111/j.1365-2036.2006.03119.x
|
| 4 |
Michael Lanuti, Geoffrey Liu, Jonathan M. Goodwin, Rihong Zhai, Bryan C. Fuchs, Kofi Asomaning, Li Su, Norman S. Nishioka, Kenneth K. Tanabe, David C. Christiani. A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome. Clinical Cancer Research 2008; 14(10): 3216 doi: 10.1158/1078-0432.CCR-07-4932
|
| 5 |
Amr Mohamed, Bassel El-Rayes, Fadlo R. Khuri, Nabil F. Saba. Targeted therapies in metastatic esophageal cancer: Advances over the past decade. Critical Reviews in Oncology/Hematology 2014; 91(2): 186 doi: 10.1016/j.critrevonc.2014.01.010
|
| 6 |
Mark Baguma‐Nibasheka, Christie Barclay, Audrey W. Li, Laurette Geldenhuys, Geoffrey A. Porter, Jonathan Blay, Alan G. Casson, Paul R. Murphy. Selective cyclooxygenase‐2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma. Molecular Carcinogenesis 2007; 46(12): 971 doi: 10.1002/mc.20339
|
| 7 |
Leon M.G. Moons, Ernst J. Kuipers, Agnieszka M. Rygiel, Anthonie Z.M. Groothuismink, Han Geldof, Willem A. Bode, Kausilia K. Krishnadath, Jacques J.G.H.M. Bergman, Arnoud H.M. van Vliet, Peter D. Siersema, Johannes G. Kusters. COX-2 CA-Haplotype Is a Risk Factor for the Development of Esophageal Adenocarcinoma. The American Journal of Gastroenterology 2007; 102(11): 2373 doi: 10.1111/j.1572-0241.2007.01373.x
|
| 8 |
M.J. Guimarães, M.I. Carvalho, I. Pires, J. Prada, A. Gonzalez Gil, C. Lopes, F.L. Queiroga. Concurrent Expression of Cyclo-oxygenase-2 and Epidermal Growth Factor Receptor in Canine Malignant Mammary Tumours. Journal of Comparative Pathology 2014; 150(1): 27 doi: 10.1016/j.jcpa.2013.07.005
|
| 9 |
Aaron Goldman, Hwu Dau Rw Chen, Heather B. Roesly, Kimberly A. Hill, Margaret E. Tome, Bohuslav Dvorak, Harris Bernstein, Katerina Dvorak. Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett's esophagus pathogenesis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2011; 300(2): G292 doi: 10.1152/ajpgi.00461.2010
|
| 10 |
Fouad Otaki, Prasad G. Iyer. Point–Counterpoint: Screening and Surveillance for Barrett’s Esophagus, Is It Worthwhile?. Digestive Diseases and Sciences 2018; 63(8): 2081 doi: 10.1007/s10620-018-5065-9
|
| 11 |
Vivianda Menke, Raymond GJ Pot, Leon MG Moons, Katinka PM van Zoest, Bettina Hansen, Herman van Dekken, Peter D Siersema, Johannes G Kusters, Ernst J Kuipers. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. Journal of Human Genetics 2012; 57(1): 26 doi: 10.1038/jhg.2011.124
|
| 12 |
Karen A. Johnson, Powel H. Brown. Drug Development for Cancer Chemoprevention: Focus on Molecular Targets. Seminars in Oncology 2010; 37(4): 345 doi: 10.1053/j.seminoncol.2010.05.012
|
| 13 |
Leslie W. Chan, Yak-Nam Wang, Lih Y. Lin, Melissa P. Upton, Joo Ha Hwang, Suzie H. Pun. Synthesis and Characterization of Anti-EGFR Fluorescent Nanoparticles for Optical Molecular Imaging. Bioconjugate Chemistry 2013; 24(2): 167 doi: 10.1021/bc300355y
|
| 14 |
Guilherme Pretto, Richard Ricachenevsky Gurski, Marcelo Binato, Daniel Navarini, Wolfgan William Schmidt Aguiar, Luise Meurer. Increase of Epidermal Growth Factor Receptor Expression in Progression of GERD, Barrett, and Adenocarcinoma of Esophagus. Digestive Diseases and Sciences 2013; 58(1): 115 doi: 10.1007/s10620-012-2316-z
|
| 15 |
Romy E. Verbeek, Peter D. Siersema, Fiebo J. Ten Kate, Kees Fluiter, Rhonda F. Souza, Frank P. Vleggaar, Pauline Bus, Jantine W. P. M. van Baal. Toll-like receptor 4 activation in Barrett’s esophagus results in a strong increase in COX-2 expression. Journal of Gastroenterology 2014; 49(7): 1121 doi: 10.1007/s00535-013-0862-6
|
| 16 |
YAPING XU, LIMING SHENG, WEIMIN MAO. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action. Oncology Letters 2013; 5(1): 19 doi: 10.3892/ol.2012.994
|
| 17 |
Jay Overholser, Kristen Ambegaokar, Siobhan Eze, Eduardo Sanabria-Figueroa, Rita Nahta, Tanios Bekaii-Saab, Pravin Kaumaya. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines 2015; 3(3): 519 doi: 10.3390/vaccines3030519
|
| 18 |
W. Y. Cheung, R. Zhai, M. H. Kulke, R. S. Heist, K. Asomaning, C. Ma, Z. Wang, L. Su, M. Lanuti, K. K. Tanabe, D. C. Christiani, G. Liu. Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis 2009; 30(8): 1363 doi: 10.1093/carcin/bgp126
|
| 19 |
Patrick Yachimski, Richard M. Peek. Biomarkers in Exploring the Frontiers of Diagnosis, Prognosis, and Therapy of Barrett's Esophagus. Cancer Prevention Research 2011; 4(6): 783 doi: 10.1158/1940-6207.CAPR-11-0204
|
| 20 |
A. L. Van Dyke, M. L. Cote, G. M. Prysak, G. B. Claeys, A. S. Wenzlaff, V. C. Murphy, F. Lonardo, A. G. Schwartz. COX-2/EGFR expression and survival among women with adenocarcinoma of the lung. Carcinogenesis 2008; 29(9): 1781 doi: 10.1093/carcin/bgn107
|
| 21 |
Gen Kusaka, Kaname Uno, Katsunori Iijima, Tooru Shimosegawa. Role of nitric oxide in the pathogenesis of Barrett’s-associated carcinogenesis. World Journal of Gastrointestinal Pathophysiology 2016; 7(1): 131-137 doi: 10.4291/wjgp.v7.i1.131
|